Show simple item record

dc.contributor.authorFatima, Razia
dc.contributor.authorAkhtar, Nasim
dc.contributor.authorYaqoob, Aashifa
dc.contributor.authorHarries, Anthony D.
dc.contributor.authorKhan, Mishal S.
dc.description.abstractObjectives All countries impacted by COVID-19 have had to change routine health service delivery. Although this has reversed some of the progress made in reducing the global burden of tuberculosis (TB) disease, there is an opportunity to incorporate lessons learned to improve TB programmes going forward. Approach We use Pakistan as a case study to discuss three important adaptations in light of COVID-19: bringing care closer to patients; strengthening primary health care systems; and proactively addressing stigma and fear. Findings COVID-19 control in Pakistan has restricted people’s ability to travel and this has forced the TB programme to reduce the need for in-person health facility visits and bring care closer to patients’ homes. Strategies that may be useful for providing more convenient care to patients in the future include: : remote treatment support using telemedicine; collaborating with private healthcare providers; and establishing community medicine collection points. As part of the response to COVID-19 in Pakistan, the out-patient departments of major tertiary and secondary care hospitals were closed, and this highlighted the importance of strengthening primary healthcare for both better pandemic and TB control. Finally, stigma associated with COVID-19 and TB can be addressed using trusted community-based health workers, such as Lady Health Workers in Pakistan.en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleBuilding better tuberculosis control systems in a post-COVID world: learning from Pakistan during the COVID-19 pandemicen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2021 The Authorsen_US
dc.source.journalInternational Journal of Infectious Diseasesen_US
dc.identifier.citationInternational Journal of Infectious Diseases. 2021, 113, Supplement 1, S88-S90.en_US
dc.source.issueSupplement 1en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal